peptidepricelab
Open the App →
§ Peptide News

Peptide News: what's actually moving

FDA actions, clinical updates, regulatory changes, and what they actually mean for researchers and the broader peptide community. Our own weekly take lives in the Dispatch; this is everyone else's headlines, annotated.

Last updated

A woman in her fifties at a kitchen counter, comparing a printed certificate of analysis to a small peptide vial in her other hand with a focused expression
Vendor & Market · August 24, 2026 · 6 min read

What a 99% Purity Label on a Peptide Vial Actually Tells You

A 99% purity label on a research peptide doesn't guarantee the vial holds 99% peptide by weight. Here's what independent testing actually shows, and why the two numbers differ.

Read the story →
A woman in her fifties doing a light dumbbell exercise at home, calm and focused, with a yoga mat on the floor nearby
Research · August 24, 2026 · 7 min read

A New Compound Spared Muscle While Boosting a GLP-1's Effects, in Mice

A UC Berkeley mouse study found a compound called TOFA spared lean muscle and boosted GLP-1 effects when combined. Here's what it actually showed, and what it doesn't mean yet.

Read the story →
A Black woman in her late forties at a near-white kitchen counter, looking thoughtfully at her phone with a coffee mug, a small medication vial and injector pen sitting nearby, in soft cool morning light
Research · August 19, 2026 · 5 min read

Women Are Microdosing GLP-1s for Anti-Aging. What the Research Actually Shows

Women are microdosing GLP-1s for anti-aging, not weight loss. What the actual inflammation and epigenetic aging research does and doesn't support.

Read the story →
A woman in her fifties in a near-white kitchen, holding her phone and looking at it with a puzzled expression, an already-opened empty shipping box on the counter in front of her.
Vendor & Market · August 19, 2026 · 4 min read

My Vendor Delisted Retatrutide — Here's What Actually Happened (and What to Do)

Your retatrutide vendor just delisted it this week. Here's what our own vendor data actually shows, and how to buy smart without rushing into panic mode.

Read the story →
A woman in her fifties at a white desk, studying a data chart on her laptop screen beside a notebook, pen, and a small vial.
Research · August 18, 2026 · 6 min read

We Counted Every CJC-1295 Study on PubMed. The Real Research Stopped in 2009.

We audited every PubMed result for CJC-1295. Five studies actually test the compound, all from 2005 to 2009, all tracing to the same small research circle.

Read the story →
A woman in her fifties in a near-white kitchen, reading a printed lab document beside a small vial on the counter
Vendor & Market · August 18, 2026 · 6 min read

Only 30% of Vendors Publish a Lab-Verifiable COA. We Checked Our Own List.

Only 30% of research-peptide vendors publish a lab-verifiable COA, a new scorecard finds. We spot-checked our own vendor list to see what that number is really measuring.

Read the story →
A woman in her fifties in a near-white entryway, holding a shipping box and checking a delivery notice on her phone in soft cool morning light.
Regulatory · August 14, 2026 · 5 min read

Eli Lilly Sues Six Sellers Over Retatrutide, and the Gray Market Isn't Going Anywhere

Lilly sued six retatrutide sellers on August 12, 2026. Here's what the suits actually target, what the FDA has said, and what tighter supply means for buyers.

Read the story →
A woman in her forties walking briskly along a city sidewalk in cool morning light, phone to her ear, a small unmarked shipping box tucked under her other arm.
Regulatory · August 7, 2026 · 5 min read

Paradigm Peptides' Owner Got 70 Months for Faking His Lab Certificates. Here's What That Actually Looked Like.

Paradigm Peptides owner Matthew Kawa got 70 months for forged lab certificates and testosterone-adulterated products. What a faked COA actually looks like.

Read the story →
A woman in her fifties walking through an outdoor market on a phone call, tote bag on her shoulder, gesturing as she talks.
Regulatory · August 7, 2026 · 5 min read

A New Nonprofit Wants to Set the First Quality Standards for Compounded Peptides. Here's What to Ask For Until It's Live.

The Peptide Council launched July 27 to accredit peptide compounding pharmacies and suppliers. It's not live yet. Here's the interim checklist to use now.

Read the story →
A woman in her early fifties walking past a shuttered, gated storefront on a sunlit sidewalk, tote bag over her shoulder, unbothered and mid-stride.
Vendor & Market · August 5, 2026 · 7 min read

Nine Vendors Closed This Year. Prices Didn't Do What You'd Expect

Nine peptide vendors closed in a year. We checked our own price data to see if it actually raised prices. Most compounds got cheaper, not more expensive.

Read the story →
A woman in her late forties mid-swing on an outdoor pickleball court, paddle forward at the moment of contact, focused and enjoying herself
Regulatory · August 4, 2026 · 4 min read

The FDA's Next Peptide Hearing Includes One Whose Key Papers Were Retracted

Five peptides go before the FDA's compounding committee by February 2027, including GHK-Cu, Melanotan II and dihexa acetate. What that means if you already buy them.

Read the story →
A woman in her fifties at a kitchen table in morning light, reading a printed research paper with a pen in her hand and an unhurried, questioning expression.
Research · August 1, 2026 · 4 min read

The Two Papers That Explained How Dihexa Works Were Retracted for Fabricated Data

Two papers that established dihexa's mechanism were retracted in April 2025 for fabricated data. What that changes, what it doesn't, and what humans were tested on.

Read the story →
A woman in her early fifties walking out of a glass-fronted medical building onto a city sidewalk in the morning, a canvas tote over one shoulder, looking ahead down the street in cool lavender light.
Research · July 29, 2026 · 6 min read

MOTS-c Finally Has a Human Trial. It Isn't Studying Women Like You.

The first registered Phase 2a trial of native MOTS-c (NCT07505745) is recruiting in prediabetes. What it measures, what it leaves out, and why the midlife metabolism question stays unanswered.

Read the story →
A grey-haired woman in her fifties resting her chin on her hand at a white desk, watching a livestreamed meeting on a laptop, an open notebook and indigo pen beside her in cool lavender light.
Regulatory · July 25, 2026 · 6 min read

An FDA Panel Just Backed BPC-157 and KPV by One Vote. Here's What That Actually Means.

The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on July 23, 2026 to recommend BPC-157 and KPV for the 503A Bulks List, over FDA staff objections. What the vote does and doesn't change.

Read the story →
A woman in her fifties reading a printed research summary at a near-white desk, a laptop with a blurred chart, a small glass vial and notebook nearby, in soft cool lavender light
Research · July 25, 2026 · 5 min read

"It Didn't Work for Me" May Be a Matching Problem, Not a Personal One

New research on GLP-1 drugs beyond weight loss: a 'hungry gut' obesity subtype that responds best to tirzepatide, semaglutide's effect on liver scarring, and aging markers. What's established and what's still early.

Read the story →
A woman in her early fifties reading a laptop showing a soft line chart at a near-white desk, a small glass vial and notebook beside her, in cool lavender light.
Regulatory · July 17, 2026 · 5 min read

The FDA Just Accepted Two Generic Tirzepatide Applications. Here's What That Actually Changes.

The FDA accepted two Sandoz applications for generic tirzepatide (Mounjaro, Zepbound). Sandoz projects $200–$400/month, but Lilly's U.S. patents run to 2036.

Read the story →
A petri dish with a bacterial culture next to a molecular model of a peptide chain and a microscopy image of mitochondria, illustrating research into a bacteria-derived cancer peptide
Research · July 15, 2026 · 6 min read

Scientists Turn Tumor Bacteria Into a Cancer Drug: Meet aurB

UIC researchers developed aurB, a bacteria-derived peptide that disables ATP synthase in tumor mitochondria, shrinking prostate tumors in animal models when combined with radiation. Published in Signal Transduction and Targeted Therapy, still preclinical.

Read the story →
A hand-drawn weekly dosing calendar in an open notebook with a pen, beside a glass vial and a syringe on a clean near-white desk under soft lavender-toned light
Research · July 14, 2026 · 5 min read

GLP-1 Dosing Mistakes Are Sending Thousands of Calls to Poison Control

A national poison control study finds GLP-1 dosing errors, not misuse, behind a sharp rise in calls. What the two most common mistakes are, and what it means for anyone measuring their own dose.

Read the story →
A clean near-white desk with an open review paper, a glass peptide vial, and a dark indigo pen under soft lavender window light
Research · July 10, 2026 · 5 min read

A New Review Maps the Peptides Studied for Healthy Aging

A 2026 Frontiers in Aging review maps nine peptides studied for healthy aging, from FDA-approved tirzepatide to research-only compounds. What it does and doesn't show.

Read the story →
A government-style regulatory document with illegible text on a cool light-grey desk, a clear glass peptide vial with a silver cap beside it and a dark indigo pen resting across the page, under soft lavender-toned window light
Regulatory · July 8, 2026 · 5 min read

What the July PCAC Meeting Means for Your Peptides

FDA's Pharmacy Compounding Advisory Committee meets July 23-24 on the compounding status of BPC-157, TB-500, and other returned peptides. What FDA's own scientists — and a conflict-of-interest question — mean for the outcome.

Read the story →
A top-down view of a fitness tracker and an open notebook with a hand-drawn declining trend line, on a clean near-white desk under soft lavender-toned light
Research · July 6, 2026 · 4 min read

People on GLP-1 Drugs Are Moving Less, New Fitbit Data Shows

New Fitbit data presented at ENDO 2026 shows daily steps and exercise minutes decline after people start a GLP-1 medication. Here's what the study found — and why body composition, not just the scale, is worth tracking.

Read the story →
A woman seen from behind steps onto a minimalist white digital bathroom scale in a soft, cool-lavender-toned bathroom, an ordinary quiet morning moment
Research · July 3, 2026 · 6 min read

Retatrutide's Phase 3 Data Just Set a New Bar — And CagriSema Isn't Far Behind

Retatrutide hit 28.3% weight loss at 80 weeks in TRIUMPH-1; CagriSema hit 22.7% in REDEFINE 1 and is under FDA review. A look at the real Phase 3 numbers behind both headlines.

Read the story →
A woman in her fifties reading on a tablet in a pale armchair, one hand resting easily against her midsection, absorbed and unhurried.
Research · June 30, 2026 · 5 min read

New Commentary Examines BPC-157 as a Gastrointestinal Cytoprotectant

A new Inflammopharmacology commentary examines BPC-157's GI cytoprotective properties from outside the Croatian group behind most BPC-157 research. Here's what it says and what it can't.

Read the story →
Two women in their early fifties walking side by side through a bright hospital atrium, mid-conversation, one listening closely to the other.
Research · June 24, 2026 · 4 min read

GLP-1s Linked to Lower Risk Across Six of Seven Cancers

An ASCO 2026 study of 10,000+ patients found GLP-1s linked to lower risk in 6 of 7 cancers. Breast, liver, colorectal, lung significant. Observational only.

Read the story →
A woman in her fifties sitting in a quiet clinic waiting area, coat folded on her lap, looking toward a window with a composed expression.
Research · June 22, 2026 · 4 min read

GLP-1 Drugs Linked to 30% Lower Breast Cancer Risk in Study of 110,000 Women

Penn Medicine's study of 111,646 women found GLP-1 users had 30%–35% lower breast cancer odds. Presented at ASCO 2026. Observational — not yet causal evidence.

Read the story →
A woman in her fifties standing at an open kitchen drawer, holding an injector pen and looking down at it, caught mid-decision.
Research · June 19, 2026 · 4 min read

Most People Who Stop GLP-1 Drugs End Up Back On Them, Conference Study Finds

Research presented at the Endocrine Society's ENDO 2026 meeting finds that stopping and restarting GLP-1 medications is more common than assumed. Here's what the data shows — and what it doesn't.

Read the story →
A woman in her fifties at a bathroom mirror with bare skin and damp hair, fingertips at her cheekbone, appraising her reflection frankly.
Research · June 18, 2026 · 4 min read

Systematic Review Finds RCT Evidence for Peptides in Skin Aging

A 2026 peer-reviewed meta-analysis of RCTs finds measurable skin benefits from oral and topical peptides including collagen peptides and matrixyl. What the data shows.

Read the story →
A woman in her fifties leaning back from her laptop at a home desk in the evening, arms folded, reading something on screen with a skeptical expression.
Regulatory · June 16, 2026 · 4 min read

FDA Sends 25 Warning Letters to Telehealth Companies Over Compounded GLP-1 Claims

FDA issued 25 warning letters to telehealth firms over compounded GLP-1 marketing claims in June 2026. What the letters target and how to read the claims.

Read the story →
A woman in her late forties on a sofa in the evening, scrolling her phone with a faintly unconvinced expression.
Research · June 10, 2026

A target-trial emulation presented at ASCO 2025 followed adults with diabetes and obesity and found GLP-1 users had a 7% lower risk of obesity-related cancer and an 8% lower risk of death than users of an older diabetes drug. The reductions were largest for colon and rectal cancer, and the benefit was clearer in women than men.

Read the story →
A woman in her late forties at a pharmacy counter, turning a small pill bottle over in her fingers and reading it with mild curiosity.
Research · June 8, 2026 · 5 min read

An Oral GLP-1 Pill Heads to Phase III: What the Elecoglipron Data Actually Show

AstraZeneca's oral GLP-1 elecoglipron showed 10.5% weight loss in Phase 2b and is advancing to Phase III. What the VISTA and SOLSTICE data show — and their limits.

Read the story →
A woman in her mid-fifties sitting on the edge of her bed in early morning light, holding a glass of water, mid-thought.
Research · June 8, 2026

Postmenopausal Women Lost 35% More Weight on Tirzepatide When They Were Also on Hormone Therapy

A Mayo Clinic retrospective study published in The Lancet found postmenopausal women using tirzepatide plus hormone therapy lost significantly more weight than those on tirzepatide alone: 17% vs 14% body weight reduction, with nearly triple the rate of major weight loss.

Read the story →
An older couple reviews a Medicare Part D coverage card with a clinician beside a GLP-1 medication pen and box, with text reading "$50 monthly copay — access begins July 1"
Regulatory · June 4, 2026 · 4 min read

Medicare Will Cover GLP-1s for Weight Loss at $50 a Month Starting July 1

CMS confirmed the Medicare GLP-1 Bridge: eligible Part D beneficiaries get Wegovy, Zepbound, or Foundayo for a $50 monthly copay from July 2026 through 2027. Here's who qualifies and how it compares to cash prices.

Read the story →
Anatomical knee joint model beside a knee X-ray and a GLP-1 injection pen, illustrating research linking GLP-1 use to fewer knee replacements
Research · June 3, 2026 · 6 min read

GLP-1 Drugs Linked to Significantly Lower Risk of Knee Replacement Surgery

A large peer-reviewed study published June 2026 found semaglutide and tirzepatide may reduce knee replacement risk by nearly 5 percentage points over 8 years.

Read the story →
Semaglutide and tirzepatide vials with a syringe beside a redacted FDA 503B proposal document stamped "Closing the Compounding Window"
Regulatory · June 1, 2026 · 6 min read

FDA Moves to End Large-Scale Compounding of Semaglutide and Tirzepatide — Comment Period Closes June 29

The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment window closes June 29, 2026. Here's what it means.

Read the story →
A researcher in a lab coat reviews a bacteriostatic water quality report showing pH and benzyl alcohol failures, beside BAC water vials and a laptop with an empty Amazon search, with text reading "9 of 11 failed basic USP standards"
Vendor & Market · May 31, 2026 · 5 min read

Amazon Removed Bacteriostatic Water from Its Marketplace. Here's the Data Behind Why.

In March 2026, third-party testing found 9 of 11 bacteriostatic water products on Amazon failed basic quality standards. Amazon removed the category shortly after. Here's what the data actually showed.

Read the story →
FDA peptide compounding 2026 regulatory changes
Regulatory · May 24, 2026 · 7 min read

Which Peptides Could Get FDA Compounding Approval This Summer - and What That Actually Means

The FDA removed 12 peptides from its restricted list in April 2026, and a July advisory committee meeting could clear 7 more for legal compounding. Here's what's actually happening and what it means.

Read the story →

Research use only. Peptide Price Lab is an editorial calculator. Nothing here is medical advice, a recommendation, or a prescription. Consult a qualified clinician before anything that meets your body.